Ludovic de Gabory1, Benjamin Verillaud2, Cécile Rumeau3, Philippe Herman2, Roger Jankowski3, Justin Michel4, Héloïse de Kermadec5, André Coste5, Geoffrey Mortuaire6, Christian Righini7, Emile Reyt7, Olivier Choussy8, Vincent Trévillot9, Louis Crampette9, Elie Serrano10, Anjarasoa Tsaranazy11, Pierre-Louis Bastier1, Sebastien Vergez10. 1. Otorhinolaryngology, Head and Neck Surgery Department, University Hospital Pellegrin, Bordeaux, France. 2. Otorhinolaryngology, Head and Neck Surgery Department, University Hospital Lariboisière, Paris, France. 3. Otorhinolaryngology, Head and Neck Surgery Department, University Hospital of Nancy, France. 4. Otorhinolaryngology, Head and Neck Surgery Department, University Hospital, Marseille, France. 5. Otorhinolaryngology, Head and Neck Surgery Department, University Hospital Creteil, France. 6. Otorhinolaryngology, Head and Neck Surgery Department, University Hospital Charles Nicolle, Lille, France. 7. Otorhinolaryngology, Head and Neck Surgery Department, University Hospital Grenoble, France. 8. Otorhinolaryngology, Head and Neck Surgery Department, University Hospital Charles Nicolle, Rouen, France. 9. Otorhinolaryngology, Head and Neck Surgery Department, University Hospital Guy de Chauliac, Montpellier, France. 10. Otorhinolaryngology, Head and Neck Surgery Department, University Hospital Rangueil-Larrey, Toulouse, France. 11. Biostatistics Department, University Hospital Pellegrin, Bordeaux, France.
Abstract
BACKGROUND: Given the particularities of olfactory neuroblastoma (ONB) and the lack of studies on the subject, a multicenter collaborative study was conducted to assess treatment strategy. METHODS: Fifty-three patients with ONB were included from the French Rare Head and Neck Cancer Expert Network (REFCOR) database: 16T1, 8T2, 19T3, and 10T4. All cases were treated endoscopically with skull base removal and repair in 26 cases (49%) and without external craniotomy. RESULTS: The overall survival (OS) and disease-free survival (DFS) rates at 5 years were 87% and 71%, respectively, with mean follow-up of 45.4 ± 26.5 months. The complication rate was 18.8% with 4 cases of meningitis. Pathological analysis showed positive margins in 26.8%, notably on the dura-mater and periorbita, without impairment of OS or DFS. Forty-eight patients received adjuvant radiotherapy on T ± N. Ten patients had a recurrence (18.9%). Six patients died of their disease. Prophylactic neck irradiation seemed to reduce the recurrence rate. CONCLUSION: Exclusively endoscopic treatment proved efficient and reliable in a large controlled series.
BACKGROUND: Given the particularities of olfactory neuroblastoma (ONB) and the lack of studies on the subject, a multicenter collaborative study was conducted to assess treatment strategy. METHODS: Fifty-three patients with ONB were included from the French Rare Head and Neck Cancer Expert Network (REFCOR) database: 16T1, 8T2, 19T3, and 10T4. All cases were treated endoscopically with skull base removal and repair in 26 cases (49%) and without external craniotomy. RESULTS: The overall survival (OS) and disease-free survival (DFS) rates at 5 years were 87% and 71%, respectively, with mean follow-up of 45.4 ± 26.5 months. The complication rate was 18.8% with 4 cases of meningitis. Pathological analysis showed positive margins in 26.8%, notably on the dura-mater and periorbita, without impairment of OS or DFS. Forty-eight patients received adjuvant radiotherapy on T ± N. Ten patients had a recurrence (18.9%). Six patients died of their disease. Prophylactic neck irradiation seemed to reduce the recurrence rate. CONCLUSION: Exclusively endoscopic treatment proved efficient and reliable in a large controlled series.
Authors: Daniel B Spielman; Andi Liebowitz; Maeher Grewal; Chetan Safi; Jonathan B Overdevest; Alfred M Iloreta; Brett E Youngerman; David A Gudis Journal: World J Otorhinolaryngol Head Neck Surg Date: 2022-03-22